|Day Low/High||6.10 / 6.33|
|52 Wk Low/High||5.13 / 9.20|
Here's two 'rules of the road' when investing in this highly volatile space.
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
Redhill has some promising drugs in its pipeline, and is well funded.